Skip to main content
Sharp Therapeutics Corp. logo

Sharp Therapeutics Corp. — Investor Relations & Filings

Ticker · SHRX ISIN · CA8200092077 TSXV Professional, scientific and technical activities
Open in API
Filings indexed 128 across all filing types
Latest filing 2026-04-10 Capital/Financing Update
Country CA Canada
Listing TSXV SHRX

About Sharp Therapeutics Corp.

https://sharptx.com/

Sharp Therapeutics Corp. is a preclinical-stage drug discovery company developing small molecule therapeutics for hereditary disorders. The core business involves leveraging its proprietary Disco(tm) platform, which integrates high-speed laboratory automation with advanced computational methods, including molecular-physics and mathematical modeling, to rapidly identify small molecules that correct protein defects. This approach is designed to deliver first-choice oral medicines for genetic diseases, offering advantages over traditional biologics. Sharp focuses on monogenic diseases to utilize an accelerated and de-risked clinical development path. Current lead programs address high unmet needs in Gaucher Disease, Familial Frontotemporal Dementia, and Niemann Pick Type-C.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Capital/Financing Update Classification · 1% confidence The document is a press release announcing the closing of the fourth tranche of a non-brokered private placement for unsecured convertible notes, detailing the amount raised, terms of the notes, insider participation, and use of proceeds. This is a direct update on the company’s financing activity rather than a full financial report, regulatory form, or simple report publication notice. Therefore, it fits the Capital/Financing Update category (CAP).
2026-04-10 English
News release - English.pdf
Capital/Financing Update Classification · 1% confidence The document is a press release announcing the closing of the fourth tranche of an unsecured convertible note private placement, detailing the amount raised, terms of the notes, insider participation, and use of proceeds. This is clearly related to company fundraising and financing activity, fitting the Capital/Financing Update category.
2026-04-10 English
Report of Distributions outside Canada (Form 72-503F).pdf
Regulatory Filings Classification · 1% confidence The document is a formal Canadian securities regulatory form (Form 72-503F) reporting distributions of convertible notes outside Canada. It is not an annual or quarterly report, earnings release, governance or management announcement, proxy, dividend notice, or other specific category. It is a mandatory regulatory filing that does not fit a more specialized category, so it falls under the fallback “Regulatory Filings (RNS).”
2026-04-07 English
Report of Distributions outside Canada (Form 72-503F).pdf
Regulatory Filings Classification · 1% confidence The document is a statutory Form 72-503F “Report of Distributions outside Canada,” a mandatory regulatory filing to securities authorities detailing the distribution of convertible notes under prospectus exemptions. It is neither an investor presentation, earnings release, proxy statement, nor a management report but a specific regulatory submission. It does not fit any specialized category (e.g., share issue announcement, capital financing press release) and serves as a compliance filing. Therefore, it falls into the catch-all “Regulatory Filings” category (RNS).
2026-04-07 English
Report of Distributions outside Canada (Form 72-503F).pdf
Regulatory Filings Classification · 1% confidence The document is a completed regulatory form (“FORM 72-503F REPORT OF DISTRIBUTIONS OUTSIDE CANADA”) filed by Sharp Therapeutics Corp. under Canadian securities rules. It details an exempt distribution of convertible notes and includes issuer details, security codes, distribution dates, and a certification section. This is neither an annual or interim report, earnings release, AGM material, nor a specific announcement like a dividend or board change. It is a generic securities regulatory filing, so it falls under the fallback category “Regulatory Filings” (RNS).
2026-04-07 English
Material change report - English.pdf
Capital/Financing Update Classification · 1% confidence The document is a Canadian SEC/NASDAQ-style Form 51-102F3 Material Change Report filed on SEDAR+ describing the closing of a tranche of a private placement of unsecured convertible notes, including details on proceeds, TSXV conditional approval, interest, conversion terms, insider participation, and postponement of a share offering. This is a direct closing of a financing activity (private placement), fitting squarely into Capital/Financing Update (CAP). It is not a mere publication announcement but a substantive financing report.
2026-04-07 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.